Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016
Published Jul 30, 2016
52 pages — Published Jul 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016, provides in depth analysis on Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted pipeline therapeutics.

The report provides comprehensive information on the Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1)
- The report reviews Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for

  
Source:
Document ID
GMDHC0432TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Overview71
Therapeutics Development83
  Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Products under Development by Stage of Development81
  Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Products under Development by Therapy Area91
  Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Products under Development by Indication101
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Products under Development by Companies132
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Therapeutics Assessment154
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action161
  Assessment by Route of Administration171
  Assessment by Molecule Type181
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Companies Involved in Therapeutics Development196
  Daiichi Sankyo Company, Limited191
  Intellipharmaceutics International Inc.201
  Mapi Pharma Ltd.211
  Pfizer Inc.221
  Prismic Pharmaceuticals, Inc.231
  Yuhan Corporation241
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Drug Profiles2515
  (palmidrol + pregabalin) Drug Profile251
  gabapentin Drug Profile261
  mirogabalin besylate Drug Profile272
  NVA-1309 Drug Profile291
  pregabalin Drug Profile304
  pregabalin CR Drug Profile342
  pregabalin CR Drug Profile361
  pregabalin ER Drug Profile371
  pregabalin IR Drug Profile381
  pregabalin XR Drug Profile391
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Dormant Projects401
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Discontinued Products411
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Featured News &Press Releases429
  Jan 11, 2016: Pfizer Voluntarily Recalls Lyrica Capsules421
  Nov 25, 2015: Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain421
  Sep 10, 2015: Actavis Wins Patent Case Over Generic Lyrica421
  Mar 30, 2015: Intellipharmaceutics Submits and was Granted a Pre-IND Meeting Request with the US FDA for Its Regabatin XR (Pregabalin Extended Release Capsules) Drug Candidate431
  Mar 12, 2015: Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA Capsules CV As A Treatment For Adolescents With Fibromyalgia431
  Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin431
  Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia441
  Dec 10, 2014: Commonly Prescribed Drug for Lower Back Pain Not Effective451
  Nov 12, 2014: Pfizer to present data on LYRICA (pregabalin) capsules at ACR 2014 Annual Meeting461
  Nov 10, 2014: US Court Issues Final Order and Judgment Approving Class Action Settlement Related To Neurontin471
  Oct 22, 2014: Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin XR (Pregabalin Extended-Release)471
  Aug 12, 2014: Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica Studies Conducted in China481
  Jun 02, 2014: Pfizer Agrees To Pay $325m To Settle Neurontin Case491
  Feb 21, 2014: Pfizer's Pregabalin Receives CHMP Positive Opinion491
  Dec 09, 2013: US Supreme Court Refuses To Hear Pfizer's Appeal On Marketing Of Neurontin501
Appendix512
  Methodology511
  Coverage511
  Secondary Research511
  Primary Research511
  Expert Panel Validation511
  Contact Us511
  Disclaimer521

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Voltage-Dependent-Calcium-Channel-Subunit-Alpha2-Delta1-CACNA2D1-Pipeline-Review-H2-2016-2088-16330>
  
APA:
Global Markets Direct - Market Research. (2016). Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Voltage-Dependent-Calcium-Channel-Subunit-Alpha2-Delta1-CACNA2D1-Pipeline-Review-H2-2016-2088-16330>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.